FINANCIAL INFORMATION

Shareholder Loan

On March 7, 2017, BeiGene Biologics Co., Ltd. entered into a Shareholder Loan Contract with
GET, pursuant to which, GET provided a shareholder loan to BeiGene Biologics Co., Ltd. with the
principal of RMB900 million at an 8% fixed annual interest rate. The term of the shareholder loan is
72 months, commencing from the actual drawdown date of April 14, 2017 and ending on April 13,
2023, unless converted earlier. On April 14, 2017, we drew down the entire RMB900 million from
GET.

Capital Commitments

We had capital commitments amounting to US$41.9 million for the acquisition of property, plant
and equipment as of March 31, 2018, which was primarily for BeiGene Guangzhou Manufacturing’s
manufacturing facility in Guangzhou, China. We had capital commitments amounting to US$43.2
million for the acquisition of property, plant and equipment as of December 31, 2017, which was
primarily for BeiGene Guangzhou Manufacturing’s manufacturing facility in Guangzhou, China. We
had capital commitments amounting to US$4.5 million for the acquisition of property, plant and
equipment as of December 31, 2016, which was primarily for building BeiGene Suzhou’s
manufacturing facility in Suzhou, China.

Other Business Agreements

We enter into agreements in the normal course of business with CROs and institutions to license
included these future payments in the table of contractual
intellectual property. We have not
obligations above since the contracts are cancelable at any time by us with prior written notice or the
licensing fees are currently not determinable.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance
sheet arrangements, such as relationships with unconsolidated entities or financial partnerships, which
are often referred to as structured finance or special purpose entities, established for the purpose of
facilitating financing transactions that are not required to be reflected on our balance sheets.

Quantitative and Qualitative Disclosure about Market Risk

Interest and Credit Risk

Financial

to credit

instruments that are potentially subject

risk consist of cash and cash
equivalents and short-term investments. The carrying amounts of cash and cash equivalents, restricted
cash and short-term investments represent the maximum amount of loss due to credit risk. We had cash
and cash equivalents of US$490.6 million, US$239.6 million and US$87.5 million, restricted cash of
US$17.5 million, nil and nil and short-term investments of US$973.4 million, US$597.9 million and
US$280.7 million at March 31, 2018, December 31, 2017 and 2016, respectively, most of which are
deposited in financial institutions outside of the PRC. Our cash and cash equivalents in the PRC are
deposited with various major reputable financial institutions. The deposits placed with these financial

— 294 —

